PurpleLab® is driven by a singular goal – to provide healthcare organizations with robust and accessible real-world data (RWD) and real-world evidence (RWE) to solve conventional and emerging challenges, including tackling medication adherence. According to the FDA[1], real-world evidence (RWE) is defined as “the clinical evidence that looks at the usage and potential benefits or…

The fact that healthcare organizations need to improve care outcomes is undeniably undisputed. To succeed, health plan leaders need to acknowledge that medical care is estimated to account for only 10% to 20% of the modifiable contributors to healthy outcomes for a population. The other 80% to 90% emanates from social determinants of health (SDOH),…

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss. In addition to treating diabetics, these medications are also used to treat obesity in diabetics as well as non-diabetics.   GLP-1 drugs…

The COVID-19 pandemic underscored the necessity for healthcare organizations to adapt swiftly. This was particularly evident with the rapid adoption of telehealth. For instance, in the first quarter of 2020, telehealth visits surged by 50% compared to 2019. As COVID-19 becomes endemic, healthcare leaders face crucial decisions on the strategic use of telehealth versus in-person…

Healthcare today is evolving into precision medicine, or what the FDA refers to as personalized medicine.  To stay competitive in the constantly shifting healthcare landscape, organizations across the healthcare ecosystem must embrace this targeted approach and leverage the tools needed to make safe decisions for their patients or populations. By unlocking insights provided from advanced…

Payers are continuously looking to improve health outcomes. Removing barriers to care and improving care access through analyzing social determinants of health (SDOH) data is a key strategy. The social determinants of health (SDOH) include education, housing, transportation, income as well as other factors including where people are born, raised, live and work that impact their…

In the ever-evolving landscape of healthcare, deciphering claims data has proven to be a formidable challenge for payers and providers alike. How does PurpleLab’s data help health plans transform their claims data into actionable insights? Watch this webinar with Dr. Russell Robbins, CMIO at PurpleLab, and Dr. Aaron Novotny, Director of Health Economics at Arkansas…

CLEAR Claims Payer & Provider Payer & Provider Download

In 2019, the National Multiple Sclerosis Society published a series of findings with updated prevalence of the disease. Current estimates place the number of people diagnosed with Multiple Sclerosis (MS) at one million people in the US; double previously reported figures. It is a costly and chronic disease without an exact known cause or biomarker,…